Denali Therapeutics Inc Cash Flow Quality Index
Denali Therapeutics Inc cash flow quality index. Denali Therapeutics Inc (DNLI) has a Cash Flow Quality Index of -0.62x as of June 2023. Operating cash flow of $-113.17 Million is below net income of $183.38 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial flexibility index of Denali Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Denali Therapeutics Inc (2020–2020)
Cash flow quality index of Denali Therapeutics Inc from 2020 to 2020. Historical Cash Flow Quality Index for Denali Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Denali Therapeutics Inc (DNLI) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Denali Therapeutics Inc Cash Flow Quality Index by Year (2020–2020)
Denali Therapeutics Inc cash flow quality index by year from 2020 to 2020. Year-by-year earnings quality comparison for Denali Therapeutics Inc. For the full cash flow conversion analysis, see Denali Therapeutics Inc operating cash flow efficiency.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 5.85x | $416.15 Million | $71.14 Million | — |